Rafael Amado
2021 - Allogene Therapeutics
In 2021, Rafael Amado earned a total compensation of $9.7M as Chief Medical Officer and Executive Vice President of Research and Development at Allogene Therapeutics, a 265% increase compared to previous year.
Compensation breakdown
| Bonus | $100,000 |
|---|---|
| Non-Equity Incentive Plan | $228,000 |
| Option Awards | $1,963,489 |
| Salary | $571,591 |
| Stock Awards | $6,839,951 |
| Other | $11,125 |
| Total | $9,714,156 |
Amado received $6.8M in stock awards, accounting for 70% of the total pay in 2021.
Amado also received $100K in bonus, $228K in non-equity incentive plan, $2M in option awards, $571.6K in salary and $11.1K in other compensation.
Rankings
In 2021, Rafael Amado's compensation ranked 1,086th out of 12,415 executives tracked by ExecPay. In other words, Amado earned more than 91.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,086 out of 12,415 | 91st |
Division Manufacturing | 373 out of 5,508 | 93rd |
Major group Chemicals And Allied Products | 134 out of 2,378 | 94th |
Industry group Drugs | 113 out of 2,099 | 95th |
Industry Biological Products, Except Diagnostic Substances | 31 out of 449 | 93rd |
Source: SEC filing on April 26, 2022.
Amado's colleagues
We found four more compensation records of executives who worked with Rafael Amado at Allogene Therapeutics in 2021.
News
Allogene Therapeutics CEO David Chang's 2021 pay jumps 30% to $10M
April 26, 2022
Allogene Therapeutics CEO David Chang's 2020 pay falls 30% to $7.8M
April 22, 2021
Allogene Therapeutics CEO David Chang's 2019 pay slips 13% to $11M
April 23, 2020
Adaptimmune Therapeutics CEO James Noble's 2018 pay jumps 58% to $2.6M
March 15, 2019